Drug Development

The draft guidance document provides support to sponsors with drugs in clinical development that treat the states of sporadic Alzheimer’s disease.

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.

Webinar Date/Time: Wed, Apr 24, 2024 11:00 AM EDT

EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

Webinar Date/Time: Tue, Mar 26, 2024 11:00 AM EDT

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

Webinar Date/Time: Tue, Apr 9, 2024 11:00 AM EDT

Webinar Date/Time: Friday, April 5, 2024 at 11amEDT | 10am CDT | 8am PDT

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

The power of collaboration is a critically important for the bio/pharma industry.

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Activation and expansion are essential for success in both autologous and allogeneic therapies.

CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.

This discussion explores how the management and analysis of vast data generated by advanced analytical technologies are revolutionizing the drug discovery and development process within the biopharma industry.

Webinar Date/Time: Tue, Apr 9, 2024 2:00 PM EDT

Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.

Webinar Date/Time: Thu, Mar 14, 2024 2:00 PM EDT

Webinar Date/Time: Wed, Mar 27, 2024 11:00 AM EDT

BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.

Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.

Webinar Date/Time: Tue, Mar 5, 2024 2:00 PM EST

The three non-commercial developers of ATMPs will benefit from enhanced support from the agency.

Webinar Date/Time: Wed, Mar 13, 2024 11:00 AM EDT